May 12, 2021 -- ESR Genomics has agreed to nonexclusively license its CRISPR/Cas9 patent portfolio to GenScript.
GenScript will use the technology to enhance its gene and cell therapy research, specifically for use with its proprietary oligonucleotide and gene synthesis technologies. The company plans to expand its portfolio to include synthetic single guide RNAs, guide RNA plasmids, and guide RNA libraries, as well as cell line engineering services.
ERS Genomics holds exclusive worldwide licenses from co-founder and recent Nobel prize winner Emmanuelle Charpentier, PhD, to the foundational intellectual property covering CRISPR/Cas9. Financial details of the deal were not disclosed.